

FEB 2006

Amended Claims

1. Transdermal pharmaceutical preparation for the treatment of Parkinson's disease containing a combination of at least two active substances, characterised in that said pharmaceutical preparation contains

- a combination of a dopamine agonist and an anticholinergically active substance, or
- a combination of L-dopa and an anticholinergically active substance, or
- a combination of a dopamine agonist and an NMDA receptor antagonist, or
- a combination of L-dopa and an NMDA receptor antagonist.

2. Pharmaceutical preparation according to claim 1, characterised in that it contains a combination of three active substances, namely:

- a combination of a dopamine agonist or L-dopa, an anticholinergically active substance, and an NMDA receptor antagonist; or
- a combination of a dopamine agonist or L-dopa, an anticholinergically active substance, and a monoamine oxidase B inhibitor.

3. Pharmaceutical preparation according to claim 1 or 2, characterised in that the group of dopamine agonists comprises lisuride, bromocriptine, pramipexol, ropinirole, rotigotine, terguride, carbergoline, apomorphine, piribedile, pergolide and 4-propyl-9-hydroxynaphthoxazine (PHNO).

4. Pharmaceutical preparation according to claim 2 or 3, characterised in that the group of monoamine oxidase inhibitors consists of monoamine oxidase B-selective inhibitors, with selegiline being particularly preferred.

5. Pharmaceutical preparation according to claims 1 to 4, characterised in that the group of anticholinergics comprises the following active substances: biperiden, trihexyphenidyl, procyclidine, biperprine, metixene, orphenadrine, scopolamine, atropine and other belladonna alkaloids, benztropine and nicotine.

6. Pharmaceutical preparation according to any one of the preceding claims, characterised in that the group of the NMDA receptor antagonists comprises memantine and amantadine.

7. Pharmaceutical preparation according to any one of the preceding claims, characterised in that it additionally contains an active substance from the group of the sympathomimetics.

8. Pharmaceutical preparation according to claim 7, characterised in that the group of sympathomimetics comprises active substances from the group of the phenylethylamine derivatives, 3,4-methylenedioxymethamphetamine being particularly preferred.

9. Pharmaceutical preparation according to any one of the preceding claims, characterised in that said pharmaceutical preparation additionally contains at least one further active substance selected from the group comprising catechol-O-methyl transferase inhibitors and decarboxylase inhibitors, with entacapone, benserazide and carbidopa being particularly preferred.

10. Pharmaceutical preparation according to any one of the preceding claims, characterised in that said pharmaceutical preparation additionally contains at least one active sub-

stance from the group of the beta blockers, preferably from the group comprising propranolol, timolol, pindolol and atenolol.

11. Transdermal pharmaceutical preparation for the treatment of Parkinson's disease, characterised in that it contains selegiline and rotigotine.

12. Pharmaceutical preparation according to any one of the preceding claims, characterised in that said pharmaceutical preparation is present as a transdermal therapeutic system, preferably in the form of an active substance patch adhering to the skin.

13. Pharmaceutical preparation according to claim 12, characterised in that the said at least two active substances are contained in different layers or compartments of the transdermal therapeutic system.